Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy.
...
Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy.
...
After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia.
...
After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia.
...
After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia.
...
The US Food and Drug Administration has restricted the sale and distribution of a permanent contraception device after learning that not all women are adequately informed of the device’s risks prior to...
The US Food and Drug Administration has restricted the sale and distribution of a permanent contraception device after learning that not all women are adequately informed of the device’s risks prior to...
The US Food and Drug Administration has restricted the sale and distribution of a permanent contraception device after learning that not all women are adequately informed of the device’s risks prior to...
The success of the DURATION-7 trial has led the US Food and Drug Administration to approve a new adjunctive therapy to basal insulin for adults with type 2 diabetes with inadequate glycemic control.
The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.
